Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

A study has found cardiovascular conditions such as high blood pressure and diabetes, which are known to contribute to brain blood vessel damage in younger populations, not to be associated with an ...

A study from the Keck School of Medicine of USC has tested a biomarker linked to vascular dementia across four separate ...

With its visual interface and constant updates, the social web is a nightmare for people with Alzheimer’s and other forms of ...

Can delaying gratification today protect your brain tomorrow? Research suggests that the ability to resist immediate rewards ...

We have long suspected that music has restorative qualities, but Daniel Levitin is now providing rigorous evidence that it ...

Johnson & Johnson (JNJ) announced that the FDA has granted Fast Track designation to its Posdinema, a monoclonal antibody ...

The New Brunswick, N.J., pharmaceutical giant said posdinemab has shown potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid from treated Alzheimer's patients, and in ...